Earnings summaries and quarterly performance for Akebia Therapeutics.
Executive leadership at Akebia Therapeutics.
John P. Butler
Detailed
President and Chief Executive Officer
CEO
EJ
Erik J. Ostrowski
Detailed
Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
NP
Nicholas P. Grund
Detailed
Senior Vice President, Chief Commercial Officer
SK
Steven K. Burke
Detailed
Senior Vice President, Research & Development and Chief Medical Officer
Board of directors at Akebia Therapeutics.
Research analysts who have asked questions during Akebia Therapeutics earnings calls.
Allison Bratzel
Piper Sandler Companies
3 questions for AKBA
Also covers: ABCL, ALXO, ARDX +7 more
JH
Julian Harrison
H.C. Wainwright & Co.
2 questions for AKBA
Also covers: ARDX, PHIO
RS
Roger Song
Jefferies
2 questions for AKBA
Also covers: AADI, ALT, ALXO +14 more
AA
Antonio Arce
H.C. Wainwright & Co.
1 question for AKBA
Also covers: CLSD, CODX, ENTA
A
Ashley
Piper Sandler
1 question for AKBA
EA
Ed Arce
WestPark Capital
1 question for AKBA
Also covers: ABUS, ARCT, AUPH +5 more
LS
Leszek Sulewski
Truist Securities
1 question for AKBA
Also covers: AMRX, ANIP, BHC +6 more
Mazahir Alimohamed
Leerink Partners
1 question for AKBA
Also covers: AMRN, AQST, LNTH +2 more
Michael
TD Cowen
1 question for AKBA
Also covers: AMRN, APH, GLBE +5 more
Michael Cherny
Leerink Partners
1 question for AKBA
Also covers: ACCD, ACH, ALGN +23 more
NN
Nabeel Nassar
Jefferies Financial Group Inc.
1 question for AKBA
NN
Nabil Nassar
Jefferies Financial Group Inc
1 question for AKBA
RC
Roanna Clarissa Ruiz
Leerink Partners
1 question for AKBA
Also covers: AQST, ARDX, CRMD +5 more
Recent press releases and 8-K filings for AKBA.
Akebia Therapeutics Reports Q4 and Full Year 2025 Financial Results, Highlights Vafseo Performance and Pipeline Advancements
AKBA
Earnings
Product Launch
New Projects/Investments
- Akebia Therapeutics reported total revenues of $57.6 million in Q4 2025 and $236.2 million for calendar year 2025, with a net loss of $12.2 million in Q4 2025 and $5.3 million for the full year 2025.
- Vafseo net product revenue was $6.2 million in Q4 2025 and $45.8 million for calendar year 2025, with Q4 sales impacted by a $4.8 million inventory drawdown at USRC. The company noted improved first refill adherence rates of approximately 87% for Vafseo in early Q1 2026 and anticipates continued growth.
- The company introduced a rare kidney disease pipeline, including praliciguat (Phase 2 for FSGS), AKB-097 (Phase 2 open-label basket trial), and AKB-9090 (Phase 1 for acute kidney injury), with initial data expected in 2027 for AKB-097 and top-line results for AKB-9090 later in 2026.
- Akebia ended 2025 with $184.8 million in cash and cash equivalents, stating existing resources are sufficient to fund operations for at least the next two years. The company also anticipates generic competition for Auryxia to expand in 2026, expecting a decrease in Auryxia revenues.
2 days ago
Akebia Therapeutics Reports Q4 and Full-Year 2025 Financial Results and Vafseo Launch Progress
AKBA
Earnings
Product Launch
New Projects/Investments
- Akebia Therapeutics reported total revenues of $236.2 million for calendar year 2025, a nearly 50% increase over 2024, primarily driven by the U.S. launch of Vafseo, which generated $45.8 million in net product revenues for the year.
- The company's net loss significantly decreased to $5.3 million for calendar year 2025, down from $69.4 million in 2024, and it ended the year with $184.8 million in cash and cash equivalents, sufficient to fund operations for at least two years.
- Despite initial challenges in the second half of 2025, Vafseo is showing signs of demand growth in Q1 2026, with over 1,000 prescribers and 24 dialysis organizations having written prescriptions.
- Akebia is advancing its pipeline with key clinical trial data expected for Vafseo (VOCAL in Q4 2026, VOICE in Q1 2027) and will host an R&D Day on April 2nd to discuss its rare kidney disease programs.
2 days ago
Akebia Therapeutics Reports Strong 2025 Revenue Growth Driven by Vafseo Launch and Reduced Net Loss
AKBA
Earnings
Product Launch
New Projects/Investments
- Akebia Therapeutics reported total revenues of $236.2 million for calendar year 2025, a significant increase from $160.2 million in 2024, primarily driven by the commercial launch of Vafseo and increased Auryxia sales. The company's net loss for 2025 substantially decreased to $5.3 million compared to $69.4 million in 2024.
- Vafseo, commercially launched in 2025, generated $45.8 million in net product revenues for the full year, with $6.2 million in Q4 2025. Q4 sales were negatively impacted by a $4.8 million inventory drawdown at USRC. The company noted improving adherence rates and expanded prescriber access, with 290,000 patients having access to Vafseo protocols.
- Auryxia net product revenues reached $181.5 million in 2025. However, Akebia anticipates generic competition for Auryxia to expand in 2026, expecting a decrease in future revenues for this product.
- Akebia ended 2025 with $184.8 million in cash and cash equivalents, which is projected to fund its current operating plan for at least the next two years. The company is also advancing its rare kidney disease pipeline, with an R&D day scheduled for April 2nd, 2026, to discuss mid-stage assets praliciguat and AKB-097, and early-stage AKB-9090.
2 days ago
Akebia Therapeutics Reports Q4 and Full Year 2025 Financial Results
AKBA
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Akebia Therapeutics reported total revenues of $57.6 million for Q4 2025 and $236.2 million for the full-year 2025, with a net loss of $12.2 million in Q4 2025 and $5.3 million for the full-year 2025.
- Vafseo net product revenues were $6.2 million in Q4 2025 and $45.8 million for the full-year 2025, and the company expects significant Vafseo revenue growth in 2026 through expanded access and improved adherence rates.
- The company's cash and cash equivalents were $184.8 million as of December 31, 2025, which is expected to fund its operating plan for at least two years, while also advancing its pipeline with enrollment in the praliciguat Phase 2 clinical trial and planning for a Phase 2 AKB-097 rare kidney disease basket trial in 2H 2026.
2 days ago
Akebia Therapeutics Updates on VAFSEO Commercialization and Pipeline Development
AKBA
Product Launch
New Projects/Investments
Guidance Update
- Akebia Therapeutics is focused on advancing its commercial product VAFSEO, a HIF-PHI for anemia in chronic kidney disease patients on dialysis, which had access to approximately 275,000 patients by the end of 2025. The company aims for VAFSEO to become the standard of care in the $1 billion ESA market, representing a $500+ million opportunity.
- Key clinical catalysts for VAFSEO include data from the VOCAL study expected by the end of 2026, and the VOICE study early 2027, both evaluating three-times-weekly (TIW) dosing.
- The company initiated a Phase II study for praliciguat in FSGS in December 2025 and plans to start a basket study for AKB-097 in rare kidney diseases (IgAN, C3G, lupus nephritis) in the second half of 2026, with data expected in 2027. Additionally, a Phase I study for AKB-9090 is expected to be completed before the end of 2026.
- Akebia reported $166 million in cash as of the end of Q3 2025, providing at least two years of cash runway.
Feb 12, 2026, 2:30 PM
Akebia Therapeutics Provides Updates on VAFSEO Launch, Pipeline Progress, and Financial Position
AKBA
Product Launch
New Projects/Investments
Guidance Update
- The VAFSEO launch, which began in January 2025, is addressing initial high discontinuation rates through the adoption of three times weekly (TIW) observed dosing, leading to reduced discontinuations. Akebia aims for VAFSEO to become the standard of care in the $1 billion ESA market, representing a $500+ million opportunity.
- The company's pipeline includes praliciguat, which initiated a Phase II study in FSGS in December 2025, and AKB-097, a tissue-targeted complement inhibitor, set to begin a basket study in the second half of 2026 for IgAN, C3G, and lupus nephritis.
- Key clinical data readouts expected include the VOCAL study by the end of 2026 and the VOICE study in early 2027, both anticipated to support VAFSEO.
- Akebia reported a strong balance sheet with $166 million in cash as of the end of Q3 2025, providing at least a two-year cash runway.
Feb 12, 2026, 2:30 PM
Akebia Therapeutics Provides Update on VAFSEO Launch and Pipeline Developments
AKBA
Product Launch
New Projects/Investments
Guidance Update
- Akebia Therapeutics is a year into the launch of VAFSEO for anemia in chronic kidney disease patients on dialysis, having achieved access to approximately 275,000 patients by the end of 2025. The company is addressing initial high discontinuation rates by implementing a three-times-weekly (TIW) observed dosing regimen, which has shown reduced discontinuation rates from over 30% to less than 10% in initial centers.
- Key clinical data readouts for VAFSEO are anticipated, with the VOCAL study expected by the end of 2026 and the VOICE study results in early 2027, both supporting TIW dosing and potential label expansion.
- The company expanded its pipeline in December 2025 by initiating a Phase II study for praliciguat in FSGS and in-licensing AKB-097. A basket study for AKB-097 in IgAN, C3G, and lupus nephritis is scheduled to begin in the second half of 2026, with data expected in 2027.
- Akebia reported a strong balance sheet with $166 million in cash as of the end of Q3 2025, providing at least two years of cash runway.
Feb 12, 2026, 2:30 PM
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
AKBA
Guidance Update
Product Launch
New Projects/Investments
- Akebia Therapeutics expects Q4 2025 Vafseo net product revenue to be in the range of $5-$6 million, with underlying patient dosing demand between $10.5 and $11.5 million, and anticipates revenue growth to resume in Q1 2026.
- The company has expanded Vafseo prescribing access to approximately 275,000 patients on dialysis and saw an 8% increase in prescribers in Q4 2025 over Q3, reaching approximately 785.
- Pipeline advancements include dosing the first patient in the Praliciguat Phase 2 clinical trial for FSGS in December 2025 and planning to initiate the AKB-097 Phase 2 rare kidney disease basket trial in 2H 2026, with initial data expected in 2027.
- Akebia reported a solid financial position with $166 million in cash & cash equivalents as of September 30, 2025.
Jan 12, 2026, 1:04 PM
Akebia Therapeutics Announces Q4 2025 Vafseo Revenue Expectations and Pipeline Progress
AKBA
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Akebia Therapeutics expects Q4 2025 Vafseo net product revenue to be between $5 million and $6 million, influenced by a $4.5 million to $5 million decrease in channel inventory. The company anticipates revenue growth to resume in Q1 2026.
- Akebia is positioned to increase Vafseo prescribing depth in 2026, with access to approximately 275,000 patients.
- The company is advancing its mid-stage rare kidney disease pipeline, having dosed the first patient in the Praliciguat Phase 2 clinical trial in December 2025 and planning to initiate the AKB-097 Phase 2 basket trial in 2H 2026.
Jan 12, 2026, 1:00 PM
Akebia Therapeutics Discusses Vafseo Launch and Pipeline Expansion
AKBA
Product Launch
New Projects/Investments
M&A
- Akebia Therapeutics is making progress with the Vafseo launch, expanding access to approximately 260,000 patients as of mid-November, following DaVita's rollout to its entire organization. Operational issues in dialysis centers are being addressed to streamline drug access.
- The company anticipates a potential drop in revenue in 2027 as Vafseo transitions from TDAPA to non-TDAPA pricing, with the price expected to decrease to levels comparable to ESAs (around $2,000-$2,500 per patient per year). This will be offset by increased volume from broader patient access post-TDAPA.
- Akebia has established a rare kidney disease pipeline, initiating a Phase 2 study for FSGS with praliciguat and acquiring AKB-097 (a complement inhibitor) for $7 million upfront plus future payments. Both products are expected to dose patients in 2026.
- The company also has earlier-stage HIF-based assets, including AKB-9090 for acute kidney injury, which will enter Phase 1 early next year, and AKB-10108 targeting complications of premature birth like retinopathy of prematurity.
- The FDA has indicated that a broader label for Vafseo in non-dialysis CKD would require a larger and longer study, which Akebia is not pursuing, but they are exploring subpopulations for potential future engagement with the FDA.
Dec 2, 2025, 9:30 PM
Quarterly earnings call transcripts for Akebia Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more